Beta Drugs Crescita futura
Future criteri di controllo 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Beta Drugs.
Informazioni chiave
n/a
Tasso di crescita degli utili
n/a
Tasso di crescita dell'EPS
Pharmaceuticals crescita degli utili | 18.4% |
Tasso di crescita dei ricavi | n/a |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | None |
Ultimo aggiornamento | n/a |
Aggiornamenti recenti sulla crescita futura
Nessun aggiornamento
Recent updates
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Beta Drugs non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.
Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.
Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
3/31/2024 | 2,957 | 364 | 193 | 309 | N/A |
12/31/2023 | 2,759 | 356 | 153 | 293 | N/A |
9/30/2023 | 2,560 | 348 | 113 | 277 | N/A |
6/30/2023 | 2,416 | 327 | 83 | 255 | N/A |
3/31/2023 | 2,271 | 307 | 52 | 234 | N/A |
12/31/2022 | 2,176 | 298 | N/A | N/A | N/A |
9/30/2022 | 2,081 | 289 | 41 | 265 | N/A |
6/30/2022 | 1,960 | 269 | 72 | 281 | N/A |
3/31/2022 | 1,838 | 248 | 102 | 296 | N/A |
12/31/2021 | 1,683 | 216 | N/A | N/A | N/A |
9/30/2021 | 1,528 | 183 | 117 | 218 | N/A |
6/30/2021 | 1,345 | 150 | 123 | 202 | N/A |
3/31/2021 | 1,161 | 117 | 128 | 186 | N/A |
12/31/2020 | 1,058 | 106 | N/A | N/A | N/A |
9/30/2020 | 956 | 95 | 21 | 138 | N/A |
6/30/2020 | 932 | 94 | -24 | 111 | N/A |
3/31/2020 | 908 | 94 | -69 | 84 | N/A |
9/30/2019 | 832 | 97 | N/A | N/A | N/A |
6/30/2019 | 746 | 89 | N/A | N/A | N/A |
3/31/2019 | 659 | 80 | -206 | 1 | N/A |
3/31/2018 | 506 | 68 | 88 | 171 | N/A |
3/31/2017 | 417 | 43 | N/A | 47 | N/A |
3/31/2016 | 264 | 11 | N/A | -4 | N/A |
3/31/2015 | 3 | -1 | N/A | 14 | N/A |
3/31/2014 | 14 | 0 | N/A | 2 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Insufficient data to determine if BETA's forecast earnings growth is above the savings rate (6.7%).
Guadagni vs Mercato: Insufficient data to determine if BETA's earnings are forecast to grow faster than the Indian market
Guadagni ad alta crescita: Insufficient data to determine if BETA's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: Insufficient data to determine if BETA's revenue is forecast to grow faster than the Indian market.
Ricavi ad alta crescita: Insufficient data to determine if BETA's revenue is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if BETA's Return on Equity is forecast to be high in 3 years time